Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-25T19:39:35.005Z Has data issue: false hasContentIssue false
  • English
  • Français

Tardive Dyskinesia

Published online by Cambridge University Press:  07 November 2014

Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
In Session
Information
CNS Spectrums , Volume 12 , Issue 10 , October 2007 , pp. 747 - 750
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Glazer, WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61(suppl 4):21–26.Google ScholarPubMed
2.Jeste, DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(suppl 9):21–24.Google ScholarPubMed
3.Kane, JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(suppl 9):16–20.Google ScholarPubMed
4.Adler, LA. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56:836–841.CrossRefGoogle Scholar
5.Lieberman, JA, Stroup, S, McEvoy, J, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Engl J Med. 2005;353:1209–1223.CrossRefGoogle Scholar
6.Jones, PB, Barnes, TR, Davies, L, et al.Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–1087.CrossRefGoogle Scholar
7.Gaebel, W, Reisbeck, M, Wölwer, W, et al.Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on schizophrenia. J Clin Psychiatry. In press.Google Scholar
8.Fleischhacker, WW, Kahn, R. Paper presented at: Winter Workshop of the American College of Neuropsychopharmacology. February 2-8, 2006: Davos, Switzerland.Google Scholar